Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.
Lu H, Klopp-Schulze L, Mukker JK, Li D, Kuroki Y, Bolleddula J, Terranova N, Goteti K, Gao W, Strotmann R, Dong J, Venkatakrishnan K. Lu H, et al. Among authors: strotmann r. Clin Transl Sci. 2024 Oct;17(10):e70050. doi: 10.1111/cts.70050. Clin Transl Sci. 2024. PMID: 39445632 Free PMC article. Review.
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM; INSIGHT 2 investigators. Wu YL, et al. Among authors: strotmann r. Lancet Oncol. 2024 Aug;25(8):989-1002. doi: 10.1016/S1470-2045(24)00270-5. Lancet Oncol. 2024. PMID: 39089305 Clinical Trial.
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.
Kleemiss M, Müller CE, Schneider M, Strotmann R, Orlowski K, Goteti K, Yanik M, Brossart P, Bauernfeind FG. Kleemiss M, et al. Among authors: strotmann r. Clin Lung Cancer. 2024 Sep;25(6):577-580. doi: 10.1016/j.cllc.2024.05.008. Epub 2024 May 25. Clin Lung Cancer. 2024. PMID: 38987049 Free article. No abstract available.
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.
Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. Xiong W, et al. Among authors: strotmann r. Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30. Cancer Chemother Pharmacol. 2022. PMID: 35771259 Free PMC article. Clinical Trial.
Adaptive gene regulation in the Striatum of RGS9-deficient mice.
Busse K, Strotmann R, Strecker K, Wegner F, Devanathan V, Gohla A, Schöneberg T, Schwarz J. Busse K, et al. Among authors: strotmann r. PLoS One. 2014 Mar 24;9(3):e92605. doi: 10.1371/journal.pone.0092605. eCollection 2014. PLoS One. 2014. PMID: 24663062 Free PMC article.
26 results